ncRNA basic information ncRNA ID: MIMAT0000721 ncRNA Database: miRBase ncRNA Name: miR-369-3p ncRNA Type: miRNA ncRNA Expression: down-regulated ncRNA Method: qRT-PCR ncRNA Target Gene: SLC35F5 ncRNA Pathway: miR-369-3p/SLC35F5 pathway Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00515 (APRD00359) Drug Name: Cisplatin Drug Method: In the study, we established for the time the up-regulation of miR-369-3p in cisplatin (DDP)-resistant nonsmall cell lung cancer (NSCLC) tissues and cells. Its deregulation was found to be correlated to the magnitude of malignancy in well-characterized LCa cells. Functionally, inhibition of miR-369-3p sensitized LCa cells to DDP and suppressed the invasive capability in the presence of DDP treatment, whereas miR-369-3p overexpression promoted DDP resistance and thereby enhanced LCa cells invasiveness. Mechanistically, bioinformatics coupled with luciferase and gain-of-function, loss-of-function assays revealed that miR-369-3p may regulate DDP chemoresistance by directly targeting the 3 untranslated region (UTR) of human solute carrier 35F5 (SLC35F5), as application of miR-369-3p inhibitors or reintroduction of epigenetically silenced SLC35F5 both individually sensitized LCa cells to DDP, but combined treatment with miR-369-3p inhibitors and SLC35F5 overexpression failed to sensitized LCa cells further to DDP-elicited cell death. Drug Response: sensitive

Cancer basic information Cancer: lung non-small cell carcinoma Tissue/Cell: cell line ( SPC-A1, SK-MES-1, H1299, A549,16HBE)

Other information Title: Attenuation of deregulated miR-369-3p expression sensitizes non-small cell lung cancer cells to cisplatin via modulation of the nucleotide sugar transporter SLC35F5. Journal: Biochem Biophys Res Commun Published: 2017 PubMed ID: 28511796